Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-RSV
- Development stage
- Phase 1
- Lead developer
- ReiThera
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-RSV is a vaccine developed by ReiThera Srl for the prevention of Respiratory Syncytial Virus (RSV) infection. It is based on a Modified Vaccinia Virus Ankara (MVA) vector that encodes the RSV viral proteins F, N, and M2-1. RSV is a common cause of severe respiratory illness, particularly in infants, immunocompromised adults, and the elderly, with no effective antiviral treatment or licensed vaccine currently available.
02
Targets
RSV N (Respiratory syncytial virus nucleoprotein)RSV F (Respiratory syncytial virus fusion protein)M2-1 (Respiratory syncytial virus transcription antitermination factor M2-1)
Beyond the preview
Go deeper on MVA-RSV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-RSV.